Just saw that Lantheus got FDA approval for their new PSMA imaging agent called PYLARIFY TruVu. It's basically an upgraded version for detecting prostate cancer metastasis - the whole PSMA targeting thing is pretty interesting from a precision medicine angle. They're rolling it out starting Q4 this year, so existing PYLARIFY users can transition pretty smoothly without major disruption. Stock took a hit initially (down almost 5% at close), but recovered slightly in after-hours. Guess the market was expecting something more dramatic? Anyway, this kind of incremental innovation in diagnostic imaging is exactly where biotech keeps grinding away. The PSMA space has been heating up, so curious to see how this competes once it's actually available.